Compare Archer-Daniels-Midland Co (ADM) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Sana Biotechnology Inc — how do they compare? Archer-Daniels-Midland Co trades at $79.67 (market cap $38.78B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Archer-Daniels-Midland Co is far larger — about 34.3× Sana Biotechnology Inc's market cap, and Archer-Daniels-Midland Co pays a 2.59% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ADM | SANA | |
|---|---|---|
Market Cap | $38.78B | $1.13B |
Sector | Consumer Staples | Health |
52-Week High | $87.32 | $5.92 |
52-Week Low | $56.00 | $2.68 |
Enterprise Value | $47.03B | $1.05B |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $79.72, down 0.96% on the day, with a bullish technical signal and strong recent earnings beats. The stock shows solid fundamentals with a P/E of 21.98 and P/S of 0.48, while revenue for 2025 was $80.27B. Recent news highlights growth in biofuels and crushing margins, with the company raising its 2026 earnings outlook after a strong Q2.
The outlook is positive, supported by raised guidance and operational strength, but risks include execution challenges and margin pressures. Analysts maintain a consensus price target of $88.00, indicating potential upside from current levels amid a predominantly hold rating sentiment.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
